Professor Peter Leedman, MBBS PhD FRACP FAHMS
Founding Scientist; Director, Harry Perkins Institute of Medical Research; Head, Laboratory for Cancer Medicine in the Perkins
Peter Leedman is a physician scientist who is the Director of the Harry Perkins Institute of Medical Research, Head of the Laboratory for Cancer Medicine in the Perkins and a Professor of Medicine at the University of Western Australia. His laboratory has focused on the mechanisms regulating expression of key therapeutic targets in cancer, and devising ways to abrogate them. His team has an internationally recognised track record of discovery in RNA biology and cancer, and their recent work in microRNAs and cancer has lead to the identification of several potential targets for new therapies.
Professor Leedman completed medicine at the University of Western Australia (UWA), then trained in endocrinology at Royal Melbourne Hospital in the mid-1980s. He completed his PhD in Medicine at the Walter and Eliza Hall Institute in Melbourne with Len Harrison on autoimmune thyroid disease from 1987-1991. From 1991-1994 he was a Lucille P Markey Fellow with Bill Chin, a Howard Hughes Investigator in the Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School in Boston where he worked on the molecular mechanisms of thyroid hormone action. He returned to WA in the mid-90s to establish his laboratory in cancer biology and RNA and to play a key role in developing WA’s premier adult medical research Institute, the Perkins.
Peter is a co-inventor on several microRNA-related patents and is a co-founder of MiReven.
Keith Giles, PhD
Keith Giles is a Postdoctoral Research Scientist at the Ronald O. Perelman Department of Dermatology at the New York University School of Medicine. Previously he was a Postdoctoral Research Fellow at the Harry Perkins Institute for Medical Research. Dr Giles has a research track record that spans the post-transcriptional regulation of gene expression in cancer cells, to the role of specific oncogenic signalling pathways in the development and progression of cancer. He has published a number of research and review articles and a book chapter on microRNAs and cancer, is a regularly invited speaker on microRNAs at scientific meetings, and has attracted competitive research funding from the National Health and Medical Research Council, the Cancer Council WA, and the Scott Kirkbride Melanoma Research Centre among others. Dr Giles has a Bachelor of Science (Medical Science) from Curtin University, a Graduate Diploma in Pathology and a PhD in Medicine from the University of Western Australia. He is a co-inventor on several microRNA-related patents and is a co-founder of MiReven.